Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, 2-COHORT, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY OF SARUPARIB (AZD5305) IN COMBINATION WITH PHYSICIAN'S CHOICE NEW HORMONAL AGENTS IN PATIENTS WITH HRRM AND NON-HRRM METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (EVOPAR-PROSTATE01)

Intervention/treatment:
SARUPARIB (AZD5305) / DAROLUTAMIDE
Medical condition:
PROSTATE CANCER
Protocol code:
D9723C00001
Control number:
277733
Status:
Active, not recruiting
Approved:
August 30, 2023
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06120491
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: MALE
Age
18 Years to 130 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Calgary, Alberta, T2N 5G2
RECRUITING
Research Site
Calgary, Alberta, T2V 1P9
RECRUITING

British Columbia

Research Site
Abbotsford British Columbia, British Columbia, V2S 2J4
WITHDRAWN
Research Site
Abbotsford British Columbia, British Columbia, V2T 1X8
RECRUITING
Research Site
Kelowna, British Columbia, V1Y 5L3
RECRUITING
Research Site
Vancouver, British Columbia, V5Z 1H7
RECRUITING

Ontario

Research Site
Kingston, Ontario, K7L 5P9
RECRUITING
Research Site
Mississauga, Ontario, L5M 2N1
WITHDRAWN
Research Site
Newmarket, Ontario, L3Y 2P9
WITHDRAWN
Research Site
Ottawa, Ontario, K1H 8L6
RECRUITING
Research Site
Toronto, Ontario, M4N 3M5
WITHDRAWN
Research Site
Toronto, Ontario, M5G 2M9
RECRUITING

Quebec

Research Site
Chicoutimi, Quebec, G7H 5H6
RECRUITING
Research Site
Greenfield Park, Quebec, J4V 2H1
RECRUITING
Research Site
Montreal, Quebec, H2X 3E4
RECRUITING
Research Site
Montreal, Quebec, H3T 1E2
RECRUITING
Research Site
Montreal, Quebec, H4A 3J1
RECRUITING
Research Site
Québec, Quebec, G1J 1Z4
RECRUITING

Saskatchewan

Research Site
Saskatoon, Saskatchewan, S7N 4H4
RECRUITING
Did you find what you were looking for?